First human test of TJ102 in advanced ovarian cancer and other solid tumors
Tests TJ102 in adults with advanced ovarian cancer or other solid tumors.
Key facts
- Who runs it
- Phrontline Biopharma
- Where
- Fairfax, Houston, Irving, Lake Success, Los Angeles, Nashville, Orlando, and Philadelphia, United StatesSee the 8 sitesAlso in 1 other country, 1 site
- Trial code
- Registry title
- A Phase I/II, First-in-Human Study to Evaluate TJ102 in Participants With Advanced or Metastatic Ovarian Cancer and Other Solid Tumors.
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 150 people, planned
- Started
- 29 Sept 2026
- Expected to end
- Sept 2030
- Type of study
- Interventional
- Treatments tested
- TJ102
- Record updated
- 12 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced or spread high-grade serous ovarian cancer who have already had platinum treatment and other standard treatments.
- Age
- 18 years or older
- Sex
- All sexes
- Disease stage
- Locally advanced or metastatic high-grade serous epithelial ovarian cancer (including fallopian tube or primary peritoneal carcinoma) that cannot be cured by surgery or radiotherapy and has grown on the latest treatment. At least one lesion measurable by RECIST v1.1. ECOG performance status 0 to 1.
- Earlier treatment
- Must have had a platinum-containing treatment. Must have had at least 1 and no more than 4 earlier lines of systemic therapy for advanced disease. Platinum-sensitive disease may join in Phase 1 only after at least 2 platinum-containing lines.
Main reasons for not taking part
- More than 2 earlier antibody-drug conjugate therapies, or earlier eribulin-based antibody-drug conjugate
- Active brain or meningeal metastases (treated and stable ones may be allowed)
- History of interstitial lung disease that needed steroids, or current lung inflammation
- Another cancer within the last 3 years (except some low-risk tumors)
- Breastfeeding
The registry criteria, word for word
Show all 26 criteriaShow less
Other criteria
- Main Inclusion Criteria:
- Has histologically or cytologically documented locally advanced or metastatic high-grade serous epithelial ovarian cancer, including ovarian, fallopian tube, or primary peritoneal carcinoma, that is not amenable to curative surgery or radiotherapy, and has demonstrated radiographic disease progression on the most recent line of systemic therapy
- Prior exposure to a platinum-containing regimen is mandatory. Platinum-resistant disease is defined as disease progression during or within 6 months following completion of the most recent platinum-containing regimen. Patients with platinum-sensitive disease may be eligible during Phase 1 if they have received at least 2 prior lines of platinum-containing systemic therapy
- Prior Lines of therapy:; Subjects must have received at least one (≥1) and no more than four (≤4) prior lines of systemic therapy in the advanced or metastatic setting and have progressed on, been intolerant to, or be ineligible for standard therapies available in their local region. Prior treatment with mirvetuximab soravtansine and/or bevacizumab is permitted but not required, reflecting regional differences in standard of care, regulatory approval status, availability, or access; Hormonal therapy and maintenance therapy, including PARP inhibitors or bevacizumab maintenance, are not counted as prior lines of systemic therapy unless administered for treatment of progressive disease
- Have at least one measurable lesion by RECIST v1.1 (Eisenhauer et al., 2009) for solid tumors
- ≥18 years old
- Eastern Cooperative Oncology Group (ECOG) performance status (Oken et al., 1982) of 0 to 1
- Life expectancy of ≥12 weeks
- Patients with adequate organ function and the laboratory test criteria specifically defined as follows within 7 days prior to the first dosing; Main Exclusion Criteria:
- Has know hypersensitivity to any component of TJ102 or has a history of severe hypersensitivity reactions to other monoclonal antibodies
- Has received more than two (2) prior antibody-drug conjugate (ADC) therapies in the advanced or metastatic disease setting, including ADCs containing topoisomerase I inhibitor payloads (e.g., SN-38, DXd, exatecan derivatives) or antimicrotubule payloads (e.g., MMAE, DM1/DM4, auristatins, maytansinoids)
- Prior therapy with any antibody-drug conjugate (ADC) whose cytotoxic payload is eribulin or a structural derivative thereof is prohibited in the advanced/metastatic disease setting
- Has received mitomycin and nitrosoureas treatment within 6 weeks prior to the first administration; oral fluorouracil-like drugs such as S-1, capecitabine, or palliative radiotherapy within 2 weeks prior to the first administration; Has received other chemotherapy, biological therapy, major surgery, radical radiotherapy, targeted therapy (including small molecule inhibitor of tyrosine kinase) and other anti-tumor therapy within 5 half-lives or 28 days, whichever is shorter, prior to the first administration of TJ102; Has received anti-tumor herbal medicine within 14 days prior to first dose of TJ102
- Has received a strong or moderate CYP3A4 inhibitor within 3 half-lives prior to first dose of TJ102
- Received an investigational drug within 28 days or 2 half-lives (whichever is shorter) prior to first dose of TJ102; Current participation in other interventional clinical studies (participation in survival follow-up is allowed)
- Toxic effects of prior anti-tumor therapy have not recovered to NCI-CTCAE V6.0 Grade ≤1 (excluding alopecia and skin pigmentation). Subject with irreversible toxicities caused by prior anti-tumor therapy (eg, hearing loss) that will not increase the safety risk may be eligible per the discretion of the Investigator
- Has a history of (non-infectious) interstitial lung disease (ILD) that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis can't be ruled out by imaging at screening
- Presence of severe dry eye syndrome, severe keratitis, severe conjunctivitis, or other severe conditions that may increase the risk of corneal epithelial damage at the discretion of investigator
- Presence of Grade ≥2 or history of Grade ≥3 peripheral neuropathy
- Uncontrolled or significant cardiovascular disease
- For patients with documented positive virology status, as confirmed by Screening hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV) tests, only the following patients may be eligible as evaluated by the sponsor and investigator:; Patients with active hepatitis B: HBV DNA ≤500 IU/mL during Screening. Patients who are hepatitis C virus antibody positive (HCV Ab+), should have controlled infection (HCV RNA≤ULN by polymerase chain reaction [PCR] either spontaneously or in response to a successful prior course of anti-HCV therapy at Screening). Patients with controlled infections must undergo periodic monitoring of HCV RNA as per treating physician
- Severe infection, including but not limited to hospitalization due to infection, bacteraemia, or severe pneumonia complications, occurs within 4 weeks prior to initiation of study treatment; Or patients who received therapeutic oral or intravenous antibiotics and who received prophylactic antibiotics (e.g., for the prevention of urinary tract infection or chronic obstructive pulmonary disease) within two weeks prior to starting study treatment
- Active central nervous system (CNS) metastases or meningeal metastases. Subjects may be enrolled in the study if their CNS metastases have received adequate local therapy and have been clinical stable for at least 4 weeks (i.e., imaging shows no progression of the brain lesion and neurologically relevant symptoms are stable), and require a dose of prednisone of ≤20 mg/day (or equivalent dose). Subjects with untreated CNS metastases are excluded
- Other malignancies within 3 years prior to initiation of study treatment (Note: does not include tumors with a negligible risk for metastasis or death, eg, non-melanoma basal cell carcinoma or squamous cell carcinoma of the skin, breast/cervical carcinoma in situ, superficial bladder carcinoma that have received radical treatment and without evidence of disease recurrence)
- Female patients who are lactating or breastfeeding
- The investigator believes that the subject may have other factors that may affect the results of the study and interfere with the subject's participation in the entire study process, including previous or existing physical conditions, abnormal treatment or laboratory tests, and the subject's unwillingness to comply with all procedures, restrictions, and requirements of the study
Where in United States
Also in 1 other country, 1 site
- NEXT VirginiaFairfax, United StatesContact: Salkeni, MohamadTaking people
- NEXT HoustonHouston, United StatesContact: Segar, JenniferTaking people
- NEXT DallasIrving, United StatesContact: Polani, FaranTaking people
- START New York Long Island, LLCLake Success, United StatesContact: Coyne, GeraldineTaking people
- South Texas Accelerated Research Therapeutics START LLCLos Angeles, United StatesContact: Hafez, NavidTaking people
- SCRI Oncology PartnersNashville, United StatesContact: Hamilton, ErikaTaking people
- Florida Cancer Specialists - Lake NonaOrlando, United StatesContact: Perez Batista, CesarTaking people
- Sidney Kimmel Cancer Center - Jefferson HealthPhiladelphia, United StatesContact: Micaily, IdaTaking people
About the trial
What the trial wants to find out
The goal of this clinical trial is to evaluate whether TJ102, an investigational antibody-drug conjugate (ADC), can safely and effectively treat patients with advanced ovarian or other solid tumors. The main objectives of this study are : • To Determine the maximum tolerated dose (MTD) and recommended dose for expansion (RDE) of TJ102 • to show preliminary antitumor activity in patients with advanced ovarian or other solid tumors. Participants will: • Receive intravenous (IV) infusions of TJ102 at escalating dose levels (during dose escalation) or at the selected expansion dose. • Undergo regular tumor imaging to assess response. • Provide blood samples for pharmacokinetics (PK) and biomarker analysis. • Be monitored for side effects and overall tolerability. This study is being conducted in adult patients with advanced or metastatic ovarian or other solid tumors who have exhausted standard treatment options.
The group in the trial
- TJ102Treatment being tested
TJ102 will be infused intravenously once every 3 weeks. Participants will receive TJ102 at escalating dose levels (during dose escalation) or at the selected expansion dose
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase I/II, First-in-Human, Open-Label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Preliminary Efficacy, and Immunogenicity of TJ102 in Participants With Advanced or Metastatic Ovarian Cancer and Other Solid Tumors.
- Plain-language title
- First human test of TJ102 in advanced ovarian cancer and other solid tumorsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 12 November 2026